A handful of drug makers have lost their battle with investors who had submitted proposals seeking more information on the potential link between executive compensation packages and rising drug prices.
Despite opposition from AbbVie, Amgen, Biogen, Bristol-Myers Squibb, and Eli Lilly, the SEC has ruled that the shareholder resolutions will appear on company ballots. Shareholders will now be able to vote on these resolutions at company annual meetings this spring.
